SORAFENAT 200MG - Applepharma

描述

索拉芬特属于蛋白激酶抑制剂的类型，索拉非尼 索拉芬特被研究作为合成化合物靶向信号反应生长和血管生成。Sorafenat,

Sorafenat, 还通过阻断肿瘤血管生成来抑制VEGFR-2 索拉非尼 / PDGFR-β信号传导力。索拉非尼

Sorafenat是一种处方药，在医学肿瘤学家的指导下使用。索拉非尼
Sorafenat 处方信息

索拉芬特适用于治疗转移性肾细胞癌患者印度版索拉非尼多少钱索拉非尼吃了真能好吗

索拉芬特适用于治疗转移性肝细胞癌患者。索拉非尼

索拉芬特适用于甲状腺癌患者的治疗。
Sorafenat 机制

索拉非尼与多种细胞内（CRAF，BRAF和突变BRAF）和细胞表面激酶（KIT，FLT-3，VEGFR-2，VEGFR-3和PDGFR-β）结合。认为各种这些激酶包括在血管生​​成中，因此索拉非尼减少了流向肿瘤的血流量。索拉非尼特异性针对Raf / Mek / Erk途径。通过禁止这些激酶，禁止含有细胞增殖和血管生成的基因转录。
吸收

口服生物利用度为38％至49％。索拉非尼

索拉芬特的高血浆浓度时间为3小时。索拉非尼
分配

索拉非尼主要与人血浆蛋白结合，范围为99.5％
代谢

除了由UGT1A9介导的葡糖醛酸化外，索拉非尼还经历由CYP3A4介导的氧化代谢。
排泄

索拉芬特的排泄通过尿液，粪便和胆汁排泄也发生。印度版索拉非尼多少钱索拉非尼吃了真能好吗

索拉非尼的未改变形式是大约51％应该在粪便中回收而不是在尿液中，也会发生胆汁排泄。

Sorafenat, 的半衰期相对为25至48小时。Sorafenat,
剂量方案 Sorafenat 平板电脑

在HCC，RCC或TC条件：

索拉芬特的常用处方剂量为400mg片剂（200mg×2片），应每日服用两次。
HCC和RCC的剂量变化

如果需要减少剂量，Sorafenat 则应在HCC和RCC中改变剂量。剂量应减少至400mg单剂量。如果需要进一步减量，则在替代日提供400mg单剂量。
与HCC相关的皮肤病毒性剂量变化Sorafenat,

1级毒性：延长索拉芬特疗法并提供局部治疗以缓解症状。

2级毒性：Sorafenat 延长索拉芬特疗法并提供局部治疗以缓解症状。如果持续发生，停止索拉芬特治疗。

3级毒性：停止索拉芬特治疗，如果需要，剂量应每天减少两次，改为单剂量。
甲状腺癌的剂量改变

首次减少剂量：应推荐600毫克Sorafenat,

第二次剂量减少：每天两次服用400毫克索拉芬特

第三剂量减少：200mg索拉芬特应作为单剂量处方。
Sorafenat,造成副作用
最常见的副作用
手足皮肤反应
肌肉骨骼疾病 索拉非尼
体重减轻
增加淀粉酶和脂肪酶
腹泻
脱发
感染
上市后不良影响 索拉非尼
骨坏死
间质性肺病
毛囊炎
白细胞减少症Sorafenat
中性粒细胞减少
贫血
Stevens Johnson综合症
血管性水肿
甲状腺功能减退症 印度版索拉非尼多少钱索拉非尼吃了真能好吗
低钙血症
低钾血症
低钠血症
萧条
周围感觉神经病变
横纹肌溶解症
血小板减少
耳鸣
充血性心力衰竭
流鼻涕
发音困难
胃食管反流Sorafenat,
Sorafenat,药物 - 药物相互作用.

Sorafenat

同时施用Sorafenat 与抗生素如新霉素导致索拉非尼的AUC耗尽。

索拉芬特的溶解度取决于pH，如果pH增加导致溶解度降低。

Sorafenat 片剂与咪达唑仑，右美沙芬或奥美拉唑同时使用时，不会导致这些药物全身暴露。

索拉芬特与其他抗肿瘤药物共同给药;

紫杉醇或卡铂：引起索拉非尼暴露的升高

卡培他滨：增加卡培他滨的暴露。

多柔比星/伊立替康：阿霉素和伊立替康的AUC升高Sorafenat

与新霉素组合：对索拉非尼的肠肝循环进行干预，导致索拉非尼暴露的消耗。

索拉芬特片与强效CYP3A4抑制剂同时使用，如酮康唑，索拉非尼的AUC无变化。
索拉芬特的禁忌症

在患有鳞状细胞肺癌的患者中，Sorafenat 与卡铂和紫杉醇联合使用是禁忌的。

如果患者禁忌Sorafenat 片剂，则会发生一些过敏反应。索拉非尼
预防

索拉芬特片治疗期间出现一些不良反应;

停止Sorafenat 的治疗 索拉非尼

索拉芬特与华法林的组合导致INR水平升高。为避免此问题，经常监测患者出血（凝血酶原时间）。

索拉芬特片应在手术过程中推迟，以防止伤口并发症。

索拉芬特与卡铂/紫杉醇联合吉西他滨/顺铂治疗鳞癌的死亡率升高：

对于患有鳞状细胞肺癌的患者，这种组合是禁忌的。印度版索拉非尼多少钱索拉非尼吃了真能好吗

索拉芬特导致QT间期延长;对有心脏病的患者避免这种疗法。

在Sorafenat治疗期间，转氨酶升高导致肝损伤并导致肝功能衰竭。

索拉芬特片剂会对胎儿造成伤害 印度版索拉非尼多少钱索拉非尼吃了真能好吗

应经常监测TSH水平并调整甲状腺替代。

经常监测血压并为此病情提供抗高血压药物。
怀孕和哺乳期
怀孕

索拉芬特片的妊娠类别：D印度版索拉非尼多少钱索拉非尼吃了真能好吗

在怀孕条件下不应推荐索拉芬特片

不建议母乳喂养

储存和处理 印度版索拉非尼多少钱索拉非尼吃了真能好吗

Sorafenat 平板电脑存储在 25oC (77oF).

保护容器免受潮湿，高温和光照
错过剂量

如果患者错过服用索拉芬特的剂量，必须咨询医生并按照说明进行操作。或者应该跳过错过的剂量并遵循常规给药方案。Sorafenat,  索拉非尼 , 印度版索拉非尼多少钱索拉非尼吃了真能好吗

我们的 联系人

    +919987711567

     info@applepharma.cn  

      applepharmaceutical@gmail.com           

VIRADAY (TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ & EMTRICITABINE)DESCRIPCIÓN

DESCRIPCIÓN ;

Los comprimidos de Viraday contienen componentes activos que tienen fármacos ( viraday precio ) antirretrovirales conocidos como tenofovir disoproxil fumarato, efavirenz, emtricitabina. Viraday ( viraday precio ) es un producto aprobado por la FDA, que es activo contra la condición de infección por VIH 1. Los componentes que contienen ( viraday precio ) son; Efavirenz: inhibidor Viraday no nucleosídico de la transcriptasa inversa Emtricitabina: inhibidores Viraday de la nucleósido transcriptasa inversa Tenofovir DF: inhibidores de la Viraday nucleósido transcriptasa inversa.

INDICACIONES

La información de Viraday prescripción común de los comprimidos de Viraday se utiliza para tratar la infección por VIH-1 si se usa solo o en combinación con otros medicamentos antirretrovirales. Un uso de Viraday (buy viraday online ) es aplicable para adultos y pacientes pediátricos de aproximadamente 12 años de edad y mayores.buy viraday online ,

MECANISMO

Efavirenz
Efavirenz muestra un movimiento hostil al retroviral al reprimir el giro de la transcriptasa, buy viraday online , que es una proteína polimerasa de ADN polimerasa coordinada con ARN viral básica.

VIRADAY 

для получения дополнительной информации, пожалуйста, нажмите на эту ссылку ниже — Viraday , viraday precio ,buy viraday online ,

NAIVEX (Dolutegravir)

描述 : 

Naivex印度药 还反对复古病毒药物，包括Dolutegravir作为功能部分。Naivex 印度价格 不应该单独使用;它可能与其他敌对逆转录病毒的经营者合并，以更好地对抗HIV-1疾病。 Naivex 印度价格 并未治愈HIV-1疾病，Naivex印度药 但用于控制体内HIV的数量，并排除艾滋病毒感染艾滋病毒的严重疾病。

迹象 :

Naivex印度药 和广泛证明用于治疗HIV-1疾病，在体重35公斤的成年人和儿科患者中不完全。 Naivex在混合时是有利的;不是分区利用 Naivex印度药
药剂学类别

两者都对逆转录病毒处方有敌意Naivex：整合酶链交换抑制剂（Integrase是负责将HIV遗传物质交换到人类染色体中的蛋白质导致创造）
工作为

Naivex印度药 （Dolutegravir）含有与HIV病毒特性相矛盾的东西，这让我感到羞耻。 Naivex被称为Integrase抑制剂，它可以通过调整整合酶来降低HIV细胞变化，从而实现对侵袭性部位和封锁贸易步骤的阻断。病毒DNA混合使细胞停止这种交易程序对HIV细胞增量周期负责。这会阻碍病毒的发展 Naivex 印度价格

剂量




患者肌酐自由，尿蛋白，尿糖应偶尔观察。 Naivex印度药：由50毫克 Dolutegravir组成
Naivex的剂量推荐

两种产品的标准认可剂量是一片应该作为单一剂量口服。 Naivex印度药 应该在有或没有用餐的情况下服用。 Naivex应该有能力服用成人患者和体重不低于35公斤的儿科
药代动力学.

吸收：

Dolutegravir的最大血浆浓度时间为2至3小时。持续状态水平达到5天内 Naivex印度药

分配：

Dolutegravir主要与人血浆蛋白结合，为98.9％ Naivex印度药

代谢：

Dolutegravir的代谢是通过UGT1A1进行的 Naivex印度药，并有一些来自CYP3A的额外承诺。

排除方法：

Dolutegravir的终端半存在是14个小时。处理的重要过程是尿液和通过粪便的未改变的框架。
药物相互影响

Naivex与通过OCT2或MATE1（多非利特或二甲双胍）释放的药物结合，导致这些药物的血浆浓度延长。 Naivex与etravirine联合导致Dolutegravir血浆传播减少。 Naivex同时用于威胁分枝杆菌，对抗惊厥或草药产品，如st。约翰斯麦汁引起Dolutegravir血浆传播的耗竭。 Dolutegravir是UGT1A3，UGT1A9，BCRP和P-gp转运蛋白的底物。 Naivex加入处方，禁止这些合成化合物或转运蛋白引起，增加Dolutegravir的血浆浓度。Naivex 印度价格 片剂是非核苷类逆转录酶抑制剂的专家用途;导致利用Naivex联盟的影响。如果Naivex片剂与蛋白酶抑制剂固化导致Dolutegravir的血浆分配减少。
安全措施

过敏反应：

这可能是禁忌症的结果

由于药物相互作用而未出现病毒学应答：

Naivex印度药 的抗药性可能发生在使用其他药物的患者身上。

安全重组问题：

一些庇护性改变疾病发生在威胁复古病毒治疗的基本时期 Naivex 印度价格

安全重组问题：

一些庇护性改变疾病发生在威胁复古病毒治疗的基本时期 Naivex印度药

副作用 :

这种疗法会产生不良反应;肝毒性过敏反应免疫重建综合征

最常见的副作用如;失眠中性粒细胞升高脂肪酶增加焦虑抑郁肌酸激酶升高 Naivex 印度价格
儿科

在儿科患者的体重不低于35公斤，对复古病毒治疗的敌意是相关的。体重不足25公斤：Naivex 印度价格 的强度不应该评估。
失败的剂量

Naivex对逆转录病毒处方不友好，如果在治疗过程中发生遗漏测量，必须直接与治疗大师一起按照他们的建议指示服用。另一方面，应避免错过剂量并采取标准时间表。

哺乳期 :

在儿科患者的体重不低于35公斤 Naivex印度药，对复古病毒治疗的敌意是相关的。体重不足25公斤：Naivex 印度价格
存储

Naivex容器应保持在25℃，保护容器远离光线，潮湿和高温。

 欲了解更多信息，请点击以下链接  :      naivex 印度仿制 , Naivex印度药 , Naivex 印度价格 ,

TAFERO (ТЕНОФОВИР АЛАФЕНАМИД 25 МГ)

 TAFERO (ТЕНОФОВИР АЛАФЕНАМИД 25 МГ)

ОПИСАНИЕ :

Tafero25 мг  Тенофовир алафенамид является антигепацивирусным и антиретровирусным препаратом. Tafero25 мг  У пациентов с ВИЧ Tafero возможно комбинирование препаратов с эмтрицитабином, кобицистатом или дарунавиром. Tafero Сначала Tafero обладает антиретровирусным действием (ингибитор нуклеозидной обратной транскриптазы), Tafero теперь Tafero обладает антигепацивирусным свойством. Tafero

ОБЛАСТЬ ПРИМЕНЕНИЯ

Таблетка  Tafero25 мг Tafero может быть использована для снижения риска заражения. вирусная передача Tafero revisión

КАТЕГОРИЯ

Антиретровирусный препарат Tafero25 мг
Анти-гепацивирусный препарат

tafnat ТАБЛЕТКА

Обычная Tafero  дозировка таблетки Tafero : одну таблетку, содержащую 25 мг тенофовира алафенамида, следует принимать в виде разовой дозы. Таблетку Tafero следует вводить вместе с пищей. В диапазоне клиренса креатинина <15 мл / мин, Tafero не Tafero revisión  рекомендуется. При декомпенсированном циррозе печени: Tafero не следует принимать. Рекомендуется Перед началом терапии: Пациентам следует исследовать инфекцию ВИЧ-1 для рекомендации комбинации других антиретровирусных препаратов у ВИЧ-1-положительных пациентов. Tafero revisión

РАБОТАЕТ

Tafero revisión   -тенофовир алафенамид (TAF) TAF является пролекарством тенофовира (исходного лекарственного средства). Сначала TAF проникает в клетки печени, поскольку обладает проницаемостью для липофильных клеток. Tafero revisión   После попадания в клетки TAF подвергается гидролизу с использованием карбоксилэстеразы-1 и образуется в виде тенофовира. Tafero revisión   Тенофовир участвует во внутриклеточном метаболизме, который фосфорилируется в тенофовир трифосфат. Тенофовир трифосфат считается активным метаболитом, который обладает противовирусным Tafero revisión  свойством и интегрируется в вирусную ДНК ферментом обратной транскриптазы гепатита В и приводит к ингибированию вирусной продукции, что приводит к обрыву вирусной цепи.  Tafero.

Tafero

для получения дополнительной информации, пожалуйста, нажмите на эту ссылку ниже  - Tafero revisión ,        Tafero  25 мг таблетка  , таферо 25 мг таблетка, Tafero25 мг , Tafero цена в Индии 

Votrient 400MG TABLET (Pazopanib Tablets) | Apple pharmaceuticals

Votrient 200MG TABLET (Pazopanib Tablets) | Apple pharmaceuticals

Votrient 400 mg  is a type of protein kinase inhibitors, the main ingredient which is used as pazopanib. It is also indicated  Votrient 400 mg tablet for the treatment of advanced kidney cancer and soft tissue sarcoma Votrient 400mg is an antineoplastics medication which interferes with the development and spreads of cancer cells in the body.

USAGE

Votrient 400 mg tablet  is used as a single agent to treat the renel cell carcinoma and its advanced stage It works by preventing the activity of proteins which are interferes with the growth and spread of cancer cells.Votrient 400 mg tablet is also used as a single regimen to treat the Soft Tissue Sarcoma, (a type of cancer that occurs in the supportive tissue of the body). The cancer can develop in muscles, blood vessels, fat tissue or in other tissues that support, surround and protect organs.

PHARMACOLOGY

Votrient 400 mg belongs to an inhibitor of potent protein kinase and selective multiple receptor tyrosine kinases (RTKs) which are described in beginning of signal transduction pathways that ready for proliferation of tumor cells and affect growth critical to cell continuity and tumor progression. RTKs comes in the blockage and involves the receptors for vascular endothelial growth factors (VEGFR-1, -2, and -3), platelet-derived growth factors (PDGFR-α and -β), and stem cell factor.

DOSAGE AND ADMINISTARTION

Votrient 400 mg  dosage for renal cell carcinoma and soft tissue sarcoma (cancer in joints, muscle) will be initially 800mg , the dose adjustment in 200mg increments or decrements dose based on tolerance but max dose in adult is 800mg/day. Moderate total bilirubin >1.5 to 3 times, Votrient dose of 200mg once daily. Votrient 400 mg hould be taken on a empty stomach (1hr before or 2hr after meals. Swallow the medicine whole don’t chew/crush. Food interaction :Avoid grapefruit juice or grapefruit juice.

Votrient 400mg

SIDE EFFECTS

Votrient 400 mg  has certain side effects, If any of the symptoms occrs or not cured then call the doctor immediately Major side effects: Diarrhae; High blood pressure; low WBC; Elevated liver function test; Blood test abnormalities; increased in bilirubin levels. Common Side effects: Nausea; loss of appetite; fatigue; blood test abnormalities (low magnesium, low glucose); weakness, stomach ache.

LACTATION

Votrient 400 mg  usage is not usually given during in pregnant women and the some doctors advice to either discontinue breastfeeding or the drug, in order to give importance of drug to the mother. The drug elimination into human milk and effects in the newborn baby is unknown.

OVERDOSAGE

there is no specific antidote for Votrient 400 mg overdose, the drug doses upto 2000 mg can be administrated and It is check out in clinical trials and overdose treatment with Votrient 400 mg  should consist of supportive measures.

Phone : +91-9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com

Website: applepharmaceuticals

Nublexa 40mg tablet - Apple pharmaceutical

Nublexa 40mg

Nublexa 40mg is an antineoplastic drug which prohibits Nublexa 40mg tablet price  the growth and spread of cancer cells in the body.
Nublexa 40mg tab  is needed to treat colorectal cancer and liver cancer.Nublexa 40 mg tablet  It is also needed to treat a rare type of tumor which can affect the esophagus, stomach, or intestines.
Nublexa 40mg tablet  is commonly Nublexa 40 mg tablet  given after other cancer regimens have been tried without success.
Nublexa 40mg is a prescription drug which is used under the supervision of medical practitioners.

INDICATION :

Nublexa 40mg tablet is indicated for the treatment of metastatic colorectal cancer (CRC) who have been Nublexa 40mg  previously treated with or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy, and an anti-EGFR therapy (see section 5.1)

Nublexa 40mg tablet  tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib

Nublexa 40mg tablet price  is indicated for the treatment of hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Nublexa 40mg tablet 

DOSAGE :

Colorectal cancer :

The  Nublexa 40mg usual dose is 160mg (four 40mg tablets) Po q Day for the first 21 days of each 28-day cycle.
Gastrointestinal stromal tumor :
The usual dose is 160mg Nublexa 40mg  (four 40mg tablets) Po q Day for the first 21 days of each 28-day cycle.
Hepatocellular carcinoma :
The usual dose is 160mg (four 40mg tablets) Nublexa 40mg Po q Day for the first 21 days of each 28-day cycle.
Follow the treatment of these conditions until disease progression or undesirable toxicity .Nublexa 40mg 

MECHANISM :

Regorafenib belongs to oral Nublexa 40mg  tumour deactivation agent which potently stops multiple protein kinases, contain kinases included in tumour angiogenesis (VEGFR1, -2, -3, TIE2), oncogenesis Nublexa 40mg  (KIT, RET, RAF-1, BRAF, BRAFV600E), metastasis (VEGFR3, PDGFR, FGFR) and tumour immunity (CSF1R). Regorafenib prohibits mutated KIT, a major oncogenic driver in gastrointestinal stromal tumours, and thereby stops tumour cell multiplication. In preclinical studies regorafenib has described potent anticancer activity in a broad spectrum of tumour models containing colorectal, gastrointestinal stromal and hepatocellular tumour models which is likely mediated by its anti-angiogenic and anti-proliferative effects. In addition, regorafenib decreased the levels of tumour analogue macrophages and has shown anti-metastatic effects in vivo. Major human metabolites (M-2 and M-5) displayed similar efficacies, compared to regorafenib in in vitro and in vivo models.
ADME

Absorption:

time to peak plasma is 4 hours and concentration is 2.5mcg/mL for single dose; 3.9mcg/mL for steady state and bioavailability is 69-83%
Distribution:
regorafenib has protein bounding about 99.5% and M-2 active metabolite is 99.8%; M-5 active metabolite is 99.95%
Metabolism:
Regorafenib is metabolized by CYP3A4 and UGT1A9
Elimination:
excreted via feces 71%; 19% urine (within 12 days of single dose)
Half-life of
Regorafenib is 28 hr
M-2 active metabolite is 25 hr.
M-5 active metabolite is 51hr.

PRECAUTION :

Myocardial ischemia and infarction seen in clinical trials; withhold Nublexa 40mg for new or acute cardiac ischemia/infarction and restart only after resolution of acute ischemic events 

While treatment with Nublexa, one case report of reversible posterior leukoencephalopathy syndrome (RPLS) reported (1 of 1100 treated patients); interrupt therapy if RPLS occurs
serious drug-induced liver injury with fatal outcome appeared in Nublexa 40mg-treated patients in clinical trials. Some of the cases, liver dysfunction resulted within the first 2 months of treatment and was characterized by a hepatocellular pattern of injury.

While treatment with Nublexa 40mg will Increases risk for haemorrhage; stop therapy for severe or life-threatening haemorrhage Nublexa 40mg

While treatment with Nublexa will Increased risk of infections resulted; most common infections contains urinary tract infections, nasopharyngitis, mucocutaneous and systemic fungal infections and pneumonia

While treatment with Nublexa will Increases risk for HFSR/PPES and rash; a higher incidence of HFSR resulted in Asian patients; discontinue and then decrease or stop regorafenib depending on severity and persistence of dermatologic toxicity

DRUG INTERACTION

Nublexa 40mg concomitant use with strong CYP3A4 inducers will decrease Regorafenib plasma concentrations and increased plasma concentration of active metabolite M-2; M-5.
Nublexa 40mg interaction with strong CYP3A4 inhibitor will increase Regorafenib plasma concentration and reduced the plasma concentration of active metabolite M-2; M-5.
Nublexa 40mg interaction with BCRP substrate will increased the plasma concentration of the BCRP substrate.
MISSED DOSE

If a dose is missed, patients must consult with a medical practitioner and follow the instructions given by them. Thereby missed dose should be avoided and follow the regular dosing schedule
STORAGE

Store the Nublexa 40mg at 25℃ (77℃)

Keep the drug in its original container bottle
Keep the bottle tightly closed after one time used.

SIDE EFFECTS : 

Common side effects occurring in greater than 30% : Nublexa 40 mg tablet
Hand-foot syndrome , Diarrhea, Low platelets, Mouth sores/inflammation, Weight loss, Infection,  Nublexa 40 mg tablet Anemia, Increased liver enzymes (AST, ALT), Fatigue, High blood  Nublexa 40mg pressure, Voice disorder (Dysphonia), Protein in the urine, Low calcium, Nublexa 40 mg tablet  Low phosphorous, Low white blood cells, Decreased appetite, Increased lipase & amylase, High bilirubin in the blood, Low sodium, Nausea. Nublexa 40mg

Less common side effects occurring in about 10-29% of patients receiving  Nublexa 40mg :

Pain, Fever, Rash, Low potassium, Decreased blood clotting, Increased bleeding, Headache, Alopecia. Nublexa 40 mg tablet .

Phone : +91-9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com

Website: applepharmaceuticals

Votrient 200 mg - Applepharmaceutical

Votrient 200 mg

Votrient 200mg is a type of protein kinase inhibitors, the main ingredient which is used as pazopanib . It is also indicated for the treatment of advanced kidney Votrient 200mg tablet  cancer and soft tissue sarcoma Votrient 200mg tablet  200MG is an antineoplastics medications which interfere with the development and spreadness of cancer cells in the body.

USAGE

Votrient 200MG is used as a single agent to treat the renel cell carcinoma and its advanced stage It works by preventing the activity of proteins which are interferes with the growth and spread of cancer cells. Votrient200mg is also used as a single regimen to treat the Soft Tissue Sarcoma, (a type of cancer that occurs in the supportive tissue of the body). The cancer can develop in muscles, blood vessels, fat tissue or in other tissues that support, surround and protect organs.

PHARMACOLOGY

Votrient 200mg belongs to an inhibitor of potent protein kinase and selective multiple receptor tyrosine kinases (RTKs) which are described in beginning of signal transduction pathways that ready for proliferation of tumor cells and affect growth critical to cell continuity and tumor progression. Votrient 200mg tablet RTKs comes in the blockage and involves the receptors for vascular endothelial growth factors (VEGFR-1, -2, and -3), platelet-derived growth factors (PDGFR-α and -β), and stem cell factor.

DOSAGE

Votrient 200mg tablet  dosage for renal cell carcinoma and soft tissue sarcoma (cancer in joints, muscle) will be initially 800mg , the dose adjustment in 200mg increments or decrements dose based on tolerance but max dose in an adult is 800mg/day. Moderate total bilirubin >1.5 to 3 times, Votrient 200mg tablet  dose of 200mg once daily. Votrient 200mg tablet  should be taken on an empty stomach (1hr before or 2hr after meals. Swallow the medicine whole don’t chew/crush. Food interaction: Avoid grapefruit juice or grapefruit juice.

OVERDOSAGE:

there is no specific antidote for Votrient 200mg tablet  overdose, the drug doses upto 2000 mg can be administrated and It is check out in clinical trials and overdose treatment with Votrient 200mg tablet  should consist of supportive measures.

DOSAGE:

Votrient 200mg tablet  dosage for renal cell carcinoma and soft tissue sarcoma (cancer in joints, muscle) will be initially 800mg , the dose adjustment in 200mg increments or decrements dose based on tolerance but max dose in adult is 800mg/day. Moderate total bilirubin >1.5 to 3 times, Votrient 200mg tablet  dose of 200mg once daily. Votrientshould be taken on an empty stomach (1hr before or 2hr after meals. Swallow the medicine whole don’t chew/crush. Food interaction :Avoid grapefruit juice or grapefruit juice.

OVERDOSAGE:

there is no specific antidote for Votrient 200mg tablet  overdose, the drug doses upto 2000 mg can be administrated and It is check out in clinical trials and overdose treatment with Votrient 200mg tablet  should consist of supportive measures.

Votrient 200mg

DRUG INTERACTION : 

Strong CYP3A4 enzyme inhibitors (e.g. ketoconazole, itraconazole, voriconazole,etc) + Votrient 200mg → Increase plasma concentration. Votrient + simvastatin → increases incidence of ALT elevation Votrient200mg + PPI e.g. esomeprazole → decreases bioavailability. Concurrent use of strong of BCRP inhibitors or P-gp (e.g. lapatinib) and inducers + Votrient 200mg →alter the exposure and distribution of pazopanib.Votrient 200mg + rifampin(strong CYP3A4 Enzyme inducers) →decreases the plasma concentration.Votrient 200mg tablet 

PRECAUTION ;

Consult the doctor before to the treatment of Votrient 200mg tablets about:

Allgeric to pazopanib or any other drug products of pazopanib, which include in prescription, over the counters,vitamins,herbal remedies. Do not take immunization or vaccination without doctors advice. Inform your doctor about pregnancy and planning to pregnant. Do not breast feed while treatment with Votrient

MISSED DOSE :

The drug dose is missed, then take the drug dose as soon as possible. If time to next dose reaches then leave the missed dose and follow the routine schedule. Do not have2 dose at one time. Please consult your doctor for further clarification.

SIDE EFFECTS :

Votrient 200mg has certain side effects, If any of the symptoms occur or not cured then call the doctor immediately Major side effects: Diarrhea; High blood pressure; low WBC; Elevated liver function test; Blood test abnormalities; increased in bilirubin levels. Common Side effects: Nausea; loss of appetite; fatigue; blood test abnormalities (low magnesium, low glucose); weakness, stomach ache.

LACTATION

Votrient 200mg usage is not usually given during in pregnant women and some doctors advice to either discontinue breastfeeding or the drug, in order to give importance of the drug to the mother. The drug elimination into human milk and effects in the newborn baby is unknown.Votrient 200mg tablet

Contact Details :

    Phone : +91-9987711567 

    Email : applepharmaceutical@gmail.com

    Email : info@myapplepharma.com

    0091-9987711567

    applepharmaceuticals

IMBRUVICA 140毫克 (依罗替尼)

描述 :

依罗替尼 是 Imbruvica 140 Mg 品牌的一种通用形式，它是一种小分子药物，可永久连接蛋白质，Bruton酪氨酸激酶（BTK），这是B细胞所必需的;该药物是治疗B细胞癌，如套细胞淋巴瘤，慢性淋巴细胞白血病和瓦尔登斯特伦巨球蛋白血症所必需的。Imbruvica 140 Mg .

Imbruvica是一种处方药，在医学实践者的指导下使用Imbruvica 140 Mg

迹象

Imbruvica适用于治疗患者的以下病症，如下所述Imbruvica 140 Mg

慢性淋巴细胞白血病或小淋巴细胞淋巴瘤Imbruvica 140 Mg

套细胞淋巴瘤Imbruvica 140 Mg

Waldenström巨球蛋白血症

边缘区淋巴瘤

移植物抗宿主病

行动机制

依鲁替尼由称为酪氨酸激酶抑制剂（TKI）的肿瘤生长抑制剂组成。

酪氨酸激酶抑制剂（TKIs）阻止称为酪氨酸激酶的化学​​Imbruvica 140 Mg信使（酶）。酪氨酸激酶促进细胞发送生长信号，因此阻止它们，停止细胞生长和分裂。

ADME 属性

Imbruvica的高血浆浓度为1-2小时，与食物一起服用药物会增加依鲁替尼的暴露Imbruvica 140 Mg。

Imbruvica的血浆蛋白水平为97.3％，Vd为10,000LImbruvica 140 Mg

依鲁替尼主要通过细胞色素P450 CYP3A代谢为各种代谢物，CYP2D6在较小程度上代谢

依鲁替尼通过粪便排泄80％，尿液排出10％

依鲁替尼的半衰期为4-6小时

剂量和给药

慢性淋巴细胞白血病/小淋巴细胞淋巴瘤

每次口服qDay，常规剂量的 Imbruvica 140 Mg 是420毫克 （三个140毫克 胶囊）Imbruvica 140 Mg capsule

与苯达莫司汀和利妥昔单抗联合使用时，常用剂量为420毫克 PO，每天给药q28d至多6个周期，直至进展或不良毒性 

Imbruvica 140 Mg capsule 

套细胞淋巴瘤 :

imbruvica的常规剂量为560毫克 Imbruvica 140 Mg（4个140毫克 -毫克 胶囊）PO qDay。

延长至疾病进展或不良毒性 .

欲了解更多信息，请点击以下链接 - Imbruvica 140 Mg , Imbruvica 140 Mg capsule , Imbruvica side effects

描述

sovihep dacihep 片剂对病毒药物具有敌意力sovihep dacihep 片剂是单次测量治疗，它是医生开处方药物，只是根据修复专家的信息，他们都在排练 达卡他韦 不是单独使用，为了更好的活动它应该与 索非布韦 平板电脑相结合。在某些情况下，sovihep dacihep 与利巴韦林联合使用，这是一种对病毒性药物的敌意，用作失代偿（儿童 普格 B或C）肝硬化的一部分. sovihep-dacihep 价格印度

为...规定

sovihep dacihep 的主要标志是;该混合片剂用于治疗由基因型I或III引起的恒定丙型肝炎病毒性疾病。使用sovihep dacihep 片剂时发生的显着限制减少了丙型肝炎基因型I或III污染患者的稳定病毒学反应率。

药理

sovihep dacihep 片的活性是通过某种机制参与发生的;

                     SOVIHEP-DACIHEP (索非布韦 & 达卡他韦)

索非布韦

含有 索非布韦 的 索非布韦  sovihep dacihep 对肝细胞病毒运动具有敌意，这是一种特异性的药物，通过禁用NS5B RNA依赖的RNA聚合酶蛋白显示其活性;肝炎病毒复制的基础。 索非布韦 被加工成框架尿苷三磷酸盐，这是一种基本的动态代谢产物，sovihep-dacihep 价格印度 它发现了对病毒作用的敌意。在NS5B聚合酶的帮助下，这种动态代谢物混合成肝炎病毒RNA并导致病毒链停止

达卡他韦

含有 达卡他韦 的 达卡他韦 通过限制病毒生成和病毒粒子收集所需的NS5A蛋白去除对病毒作用的敌意     sovihep-dacihep 价格印度

剂量

sovihep dacihep 片剂有或没有食物，在由基因型I或III引起的慢性丙型肝炎病毒感染的情况下，Sovihep dacihep 是单剂量疗法   sovihep-dacihep 价格印度

剂量方案

达卡他韦 通常不单独使用治疗，它与 索非布韦 联合使用sovihep dacihep 的建议剂量是一片应该作为单剂量服用如果停用 索非布韦 ，sovihep-dacihep 价格印度  达卡他韦 也会停止基因型I患者没有肝硬化或代偿性肝硬化：推荐的常用剂量为sovihep dacihep ，一片服用单剂量，有或没有食物。在失代偿期肝硬化患者中：sovihep dacihep 应与利巴韦林一起作为单剂量服用

基因型III

患者无肝硬化或代偿性肝硬化：推荐的常用剂量为sovihep dacihep ，一片应以单剂量给药，有或没有食物。在失代偿期肝硬化患者中：sovihep dacihep 应与利巴韦林一起服用，每日一次。利巴韦林的剂量;患者的血红蛋白水平，剂量可以根据体重计算。

75公斤以下：剂量为1000毫克利巴韦林;对于基因型I或III，建议使用600毫克利巴韦林作为主要剂量，然后以1000毫克 /每小鼠75公斤进行施用：给予失代偿期肝硬化的1200毫克利巴韦林剂量，每日两次。 达卡他韦 的安全性和有效性尚未确定<18年 索非布韦 使用≥12年或重量≥35公斤sovihep-dacihep 价格印度

药代动力学

分配

达卡他韦 片剂的分布容量为47L 达卡他韦 与人血浆蛋白结合的近99％ 索非布韦 的血浆与血浆比率相对为0.7 索非布韦 与人血浆蛋白结合的比例接近61％至65％sovihep-dacihep 价格印度

代谢

索非布韦 在肝脏中代谢并形成动态代谢产物尿苷三磷酸，在组织蛋白酶A或羧酸酯酶1的帮助下经历代谢，在CYP3A4的辅助下发生 达卡他韦 消化 sovihep-dacihep 价格印度

消除

达卡他韦 的近88％通过粪便排出; sovihep-dacihep 价格印度 53％为母公司形式;通过尿液排出6.6％。 索非布韦 代谢产物通过尿液排出80％，粪便排出14％，呼出空气排出2.5％ 索非布韦 的终末半衰期达到0.51小时; 达卡他韦 半衰期为12至15小时.

欲了解更多信息，请点击以下链接 -   sovihep-dacihep 价格印度 , sovihep dacihep  副作用 , sovihep dacihep , sofosbuvir

我们的 联系人

    +919987711567

     info@applepharma.cn  

     applepharmaceutical@gmail.com